Hideaki Mizutani

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 235 citations

Medicine, Pharmacology, Pharmacotherapy +16

MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting <i>MAGI2</i> in Lung Adenocarcinoma Cells

Kazuhiro Kitamura, Masahiro Seike, Tetsuya Okano et al. · Molecular Cancer Therapeutics · 2013 · 186 citations · Full text

Medicine, Cancer Biology, Oncology +17

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells

Mengru Cao, Masahiro Seike, Chie Soeno et al. · International Journal of Oncology · 2012 · 169 citations · Full text

Life Sciences, Cell Biology, Oncology +17

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · Journal of Thoracic Oncology · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacotherapy +17